Abstract
Both amyloid light chain (AL) amyloidosis and transthyretin-related (TTR) amyloid have been viewed with reluctance to proceed with heart transplant. AL amyloid in particular has been a contraindation for heart transplant as the underlying disease process progresses. In the current era of proteasome inhibitors, AL amyloid patients may now be adequately treated and undergo heart transplant with subsequent bone marrow transplant. In our program, we have treated 7 AL amyloid patients who developed end-stage heart disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
